Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alamar Biosciences filings document its transition to a Nasdaq-listed public company, its proteomics business, and its formal reporting of operating results, capital structure, and governance. Registration materials describe the company’s NULISA-based Precision Proteomics platform, product categories, single-segment structure, and common stock offering.
The company’s 8-K filings cover public-company events including quarterly financial results, completion of its initial public offering, amended and restated certificate of incorporation, amended and restated bylaws, and related exhibits. Its S-1/A registration statement documents IPO-related disclosures, risk factors, business description, securities registration, and governance information.
Alamar Biosciences, Inc. (ALMR) reported that director Robert P. Ragusa received equity awards on September 1, 2026. He was granted 5,686 restricted stock units, which vest in equal annual installments over three years starting September 1, 2026, subject to his continuous service. He also received a stock option for 25,599 shares of common stock at an exercise price of $29.36 per share, expiring August 31, 2036; one-third of these option shares vest on September 1, 2027, with the remainder vesting in equal monthly installments through September 1, 2029, contingent on continued service. Following these grants, he holds 5,686 shares of common stock directly and 25,599 option shares related to this award, and no Rule 10b5-1 trading plan is reported.
Alamar Biosciences, Inc. (ALMR) has a new insider disclosure, as Robert P. Ragusa, serving as a director, filed an initial Form 3 reporting his status as an insider. The filing shows no reported transactions or holdings of Alamar Biosciences securities at this time.
Alamar Biosciences, Inc. (ALMR) reported that its board of directors appointed Robert Ragusa to the board effective September 1, 2026. He will serve as a Class I Director with an initial term expiring at the company’s 2027 Annual Meeting of Stockholders.
Ragusa was also appointed to the board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. He will receive compensation under the company’s Non-Employee Director Compensation Policy and will enter into its standard indemnification agreement. The company states there were no arrangements leading to his selection and no related person transactions requiring disclosure.
Alamar Biosciences, Inc. reports that Yuling Luo has filed a Schedule 13G disclosing beneficial ownership of 4,528,718 shares of Alamar Biosciences common stock. This represents 6.4% of the company’s outstanding common stock, based on 69,387,732 shares outstanding as of June 30, 2026.
The filing indicates Luo has 3,304,566 shares with sole voting and dispositive power and 1,224,152 shares with shared voting and dispositive power. The aggregate includes 1,440,501 shares issuable within 60 days of June 30, 2026 upon exercise of stock options, and 1,224,152 shares held by Luo’s spouse.
Alamar Biosciences, Inc. has a significant shareholder group associated with Qiming funds reporting ownership of its common stock, par value $0.0001 per share. As of a base of 69,311,186 shares outstanding as of April 30, 2026, Qiming Corporate GP VI, Ltd and related entities report beneficial ownership positions on a Schedule 13G.
Qiming Corporate GP VI, Ltd is reported as beneficially owning 7,066,573 shares, or 10.2% of the class, with sole voting and dispositive power, representing 6,881,410 shares held by Qiming Venture Partners VI, L.P. and 185,163 shares held by Qiming Managing Directors Fund VI, L.P., while disclaiming beneficial ownership except for proportionate pecuniary interests. Additional Qiming-related entities report sole voting and dispositive power over stakes of 1,605,645 shares (2.3%) and 1,922,329 shares (2.8%), also with similar beneficial ownership disclaimers.
Alamar Biosciences, Inc. reported continued high growth with expanding losses for the quarter ended June 30, 2026. Revenue rose to $29.4 million from $16.2 million a year earlier, driven by higher product sales (instruments and consumables) and services across the U.S., EMEA and APAC. Six‑month revenue reached $55.5 million versus $29.3 million in 2025.
Gross profit more than doubled to $17.7 million, but higher research and development and selling, general and administrative expenses lifted the quarterly net loss to $13.2 million from $7.0 million. For the first half of 2026, net loss was $34.5 million. Operating cash outflow was $31.7 million over six months, partly offset by interest income.
The company strengthened its balance sheet through its April 2026 IPO, issuing 12,937,500 shares at $17.00 per share, for $197.8 million in net proceeds. Convertible preferred stock and notes converted into common equity, lifting total stockholders’ equity to $312.9 million. As of June 30, 2026, total assets were $391.0 million, including cash, cash equivalents and short‑term investments of about $250 million, supporting ongoing investment in its Precision Proteomics platform despite continuing losses.
Alamar Biosciences, Inc. reported strong growth for the quarter ended June 30, 2026. Total revenue was $29.4 million, up 82% from $16.2 million a year earlier. Instruments contributed $7.8 million, consumables $15.5 million, and services and other revenue $6.2 million, with consumable revenue rising 147% year-over-year on demand for multiplex panels. Gross margin improved to 60% from 53%, driven by manufacturing efficiencies and a revenue mix shift toward higher-margin consumables.
Operating expenses increased to $31.2 million, up 89% from $16.5 million, reflecting higher headcount, infrastructure, R&D investments and public company costs. Operating loss widened to $13.5 million from $7.9 million, and net loss was $13.2 million versus $7.0 million, with net loss per share of $(0.22) compared with $(0.62). Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million as of June 30, 2026. For full year 2026, the company forecasts revenue of $116–$120 million, representing 59% growth at the midpoint over 2025.
Alamar Biosciences, Inc. reported that board member Ian Ratcliffe, an independent director since February 2024, passed away on July 5, 2026. The company expressed condolences and acknowledged his dedication and service.
Following his passing, the board reduced the authorized number of directors constituting the full board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the board.
Alamar Biosciences, Inc. shareholder Sands Capital Life Sciences Pulse Fund II, L.P. reports beneficial ownership of 4,230,926 shares of common stock, or about 6.1% of the company. This percentage is based on 69,311,186 shares outstanding as of April 30, 2026.
The shares are held for investment purposes, and the reporting group may buy or sell more stock over time. Following the passing of Ian Ratcliffe on July 5, 2026, the group no longer has a representative on Alamar’s board and states it does not currently intend to seek board representation, while reserving flexibility on future plans.
Alamar Biosciences disclosure: Sherpa-related entities and manager Daqing Cai reported beneficial ownership of 4,972,134 shares of Common Stock, equal to 7.2% of the class. The filing breaks ownership into 3,970,446 shares by Sherpa Healthcare Fund II, L.P. and 1,001,688 shares by Sherpa Healthcare Co-Investment Fund, L.P. The percentage figures use a base of 69,311,186 shares outstanding as of April 30, 2026, per the company Form 10-Q.